Novel glyproline GZK-111 with neuropsychotropic activity
https://doi.org/10.37489/2587-7836-2021-4-18-23
Abstract
Thе article represents a review of our own researches, which describes the design, synthesis and pharmacological properties of linear substituted glyproline GZK-111, a potential drug for the complex treatment of psychiatric pathologies, including anxiety, depressive disorders, and cognitive impairment. The relationship between structure and activity in a series of this glyproline analogs is described. The experimental evidence of the GZK-111 ability to metabolized with the formation of cycloprolylglycine, which is identical to the endogenous cyclic dipeptide, is presented. The data on toxicological and pharmacokinetic studies of GZK-111 are presented.
About the Authors
K. N. Koliasnikova
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Koliasnikova Ksenia N. - PhD in Biology, Senior Researcher at the Laboratory of Peptide Bioregulators of the Department of Drug Chemistry
SPIN code: 5682-2035
Moscow
A. G. Alyaeva
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Alyaeva Anna G. -Junior Researcher at the Laboratory of Peptide Bioregulators of the Department of Drug Chemistry
Moscow
E. A. Kuznetsova
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Kuznetsova Elena A. - PhD in Chemical, Senior Research at the Laboratory of fine organic synthesis Department of medicinal chemistry
Moscow
References
1. Гудашева Т.А., Островская Р.У., Максимова Ф.В. и др. Топологические аналоги пирацетама на основе пролина и их ноотропная активность. Химико-фармацевтический журнал. 1989;23(3):276–281.
2. Gudasheva TA, Boyko SS, Akparov VKh, Ostrovskaya RU, Skoldinov SP, Rozantsev GG, Voronina TA, Zherdev VP, Seredenin SB. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Letters. 1996;391(1-2):149–152. DOI: 10.1016/0014-5793(96)00722-3.
3. Tran LH, inventor; Neurobiomed Corp, assignee. Neuroprotection and neuroegenisis by administering cyclic prolyl glycine. United States patent US 7232798B2. 2007.
4. Guan J, Mathai S, Harris P, Wen J-Y, Zhang R, Brimble M, Gluckman P. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia– ischemia in adult rats. Neuropharmacology. 2007;53(6):749–762. DOI: 10.1016/j.neuropharm.2007.08.010.
5. Gudasheva TA, Ostrovskaya RU, Trofimov SS, et al. New Endogenous Dipeptide Cycloprolyl-Glycine Is Similar To Piracetam By Its Mnemotropic Selectivity. Bulletin of experimental biology and medicine. 1999;128(4):411–413. (In Russ).
6. Gudasheva TA, Konstantinopol'skii MA, Ostrovskaya RU, Seredenin SB. Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test. Bull Exp Biol Med. 2001;131(5):464–466. DOI: 10.1023/a:1017928116025.
7. Seredenin SB, Gudasheva TA, Boiko SS, Kovalev GI, Voronin MV, Yarkova MA. Endogenous dipeptide cycloprolylglycine shows selective anxiolytic activity in animals with manifest fear reaction. Bull Exp Biol Med. 2002;133(4):360–362. DOI: 10.1023/a:1016293904149.
8. Vasil'eva EV, Abdullina AA, Salimov RM, Gudasheva TA, Kovalev GI. Dynamics of cycloprolylglycine psychotropic effects in BALB/C and C57BL/6 mice depending on treatment duration. Eksperimental'naya i Klinicheskaya Farmakologiya. 2021;84(1):3–7 (In Russ). DOI: 10.30906/0869-2092-2021-84-1-3-7.
9. Kolyasnikova KN, Gudasheva TA, Nazarova GA, et al. Similarity of Cycloprolylglycine to Piracetam in Antihypoxic and Neuroprotective Effects. Eksperimental'naia i klinicheskaia farmakologiia. 2012;75(9):3–6. (In Russ).DOI: 10.30906/0869-2092-2012-75-9-3-6.
10. Povarnina PY, Kolyasnikova KN, Nikolaev SV, Antipova TA, Gudasheva TA. Neuropeptide cycloprolylglycine exhibits neuroprotective activity after systemic administration to rats with modeled incomplete global ischemia and in vitro modeled glutamate neurotoxicity. Bull Exp Biol Med. 2016;160(5):653–655. DOI: 10.1007/s10517-016-3241-5.
11. Ferro JN, de Aquino FL, de Brito RG, dos Santos PL, Quintans Jde S, de Souza LC, de Araújo AF, Diaz BL, Lucca-Júnior W, Quintans-Júnior LJ, Barreto E. Cyclo-Gly-Pro, a cyclic dipeptide, attenuates nociceptive behavior and inflammatory response in mice. Clin Exp Pharmacol Physiol. 2015;42(12):1287–1295. DOI: 10.1111/1440-1681.12480.
12. Kovalev GI, Abdullina AA, Vasil'eva EV, Gudasheva TA, Seredenin SB. Antidepressant-Like Properties of Cycloprolylglycine. Eksperimental'naya i klinicheskaya farmakologiya. 2018;81(11):3–6. (In Russ). DOI: 10.30906/0869-2092-2018-81-11-3-6.
13. Garibova TL, Gudasheva TA, Seredenin SB. A New Component in the Mechanism of Regulation of Endogenous Depressive-Like States. Dokl Biochem Biophys. 2019;488(1):324–326. DOI: 10.1134/S1607672919050107.
14. Gudasheva TA, Koliasnikova KN, Seredenin SB, et al. Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors. Dokl Biochem Biophys. 2016;471(1):387–389. DOI: 10.1134/S160767291606003X.
15. Gudasheva TA, Koliasnikova KN, Antipova TA, Seredenin SB. Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells. Dokl Biochem Biophys. 2016;469(1):273– 276. DOI: 10.1134/S1607672916040104.
16. Aguado-Llera D, Canelles S, Fernández-Mendívil C, Frago LM, Argente J, Arilla-Ferreiro E, López MG, Barrios V. Improvement in inflammation is associated with the protective effect of Gly-Pro-Glu and cycloprolylglycine against Aβ-induced depletion of the hippocampal somatostatinergic system. Neuropharmacology. 2019;151:112–126. DOI: 10.1016/j.neuropharm.2019.04.008.
17. Gudasheva TA, Povarnina PY, Koliasnikova KN, Alyaeva AG, Vorontsova ON, Seredenin SB. The Anxiolytic Effect of the Neuropeptide Cycloprolylglycine Is Mediated by AMPA and TrkB Receptors. Dokl Biochem Biophys. 2020;493(1):190–192. DOI: 10.1134/S1607672920040067.
18. Koliasnikova KN, Alyaeva AG, Vorontsova ON, Gudasheva TA. Study of the involvement of AMPA receptors in the antihypoxic effect of the neuropeptide cycloprolyl- glycine. Problems of biological, medical and pharmaceutical chemistry. 2020;23(9):42–45. (In Russ) DOI: 10.29296/25877313-2020-09-06.
19. Ovchinnikov YuA, Ivanov VT. Conformational states and biological activity of cyclic peptides. Tetrahedron. 1975;31(18):2177–2209. DOI: 10.1016/0040-4020(75)80216-X.
20. Baldoni HA, Zamarbide GN, Enriz RD, Jauregui EA, Farkas Ö, Perczel A, Salpietro SJ, Csizmadia IG. Peptide models XXIX. cis–trans Isomerism of peptide bonds: ab initio study on small peptide model compound; the 3D-Ramachandran map of formylglycinamide. J Molec Struct (Theochem). 2000;500(1-3):97–111. DOI: 10.1016/S0166-1280(00)00372-9.
21. Rydon HN, Smith PWG. Polypeptides. Part IV. The self-condensation of the esters of some peptides of glycine and proline. J Chem Soc. 1956;3642– 3650. DOI: 10.1039/JR9560003642.
22. Manabe S, Machida H, Aihara Y, Yasunaga M, Ito Y, Matsumura Y. Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an antibody–drug conjugate. Med Chem Comm. 2013;4(5):792– 796. DOI: 10.1039/C3MD00075C.
23. Gudasheva TA, Kolyasnikova KN, Kuznetsova EA, Litvinova SA, Zolotov NN, Voronina TA, Ostrovskaya RU, Seredenin SB. N-phenylacetyl-glycyl- L-proline ethyl ester converts into cyclo-L-prolyl-glycine showing a similar spectrum of neuropsychotropic activity. Khimiko-Farmatsevticheskii Zhurnal. 2016;50(11):3–8. (In Russ). DOI: 10.30906/0023-1134-2016-50-11-3-8.
24. Patent RUS №2646604/ 06.03.18. Byul. № 7. Seredenin SB, Gudasheva TA, Koliasnikova KN, Kuznetsova EA, Voronina TA, Yarkova MA, Antipova TA, Litvinova SA, Zolotov NN. Novyye gliproliny s nootropnoy, antigipoksicheskoy, neyroprotektivnoy i anksioliticheskoy aktivnost'yu (In Russ).Доступно по: https://findpatent.ru/patent/264/2646604.html Ссылка активна на 14.12.2021.
25. Kolyasnikova KN, Kuznetsova EA, Nikolaev SV, Antipova TA, Gudasheva TA, Seredenin SB. Investigation of the structure – antihypoxic activity relationship in a series of substituted glyprolines. Khimiko-Farmatsevticheskii Zhurnal. 2018;52(6):13– 17. (In Russ).DOI: 10.30906/0023-1134-2018-52-6-13-17.
26. Nikolaev SV, Logvinov IO, Koliasnikova KN, Kuznetsova EA, Antipov PI, Antipova TA. The in vitro neuroprotective activity of analogues of N-terminus substituted glyprolines. Farmakokinetika i farmakodinamika. 2020;(2):4–10. (In Russ). DOI: 10.37489/2587-7836-2020-2-4-10.
27. Kuznetsova EA, Kolyasnikova KN, Golubyatnikova AK, Rebeko AG, Gudasheva TA. Developing the optimal synthetic schem for the potential nootropic drug GZK-111, N-phenylacetylglycyl-L-proline ethyl ester. Pharmaceutical chemistry journal. 2020; 54(6):642–646. DOI: 10.1007/s11094-020-02251-6.
28. Litvin AA, Kolyvanov GB, Bochkov PO, et al. Preclinical pharmacokinetics of dipeptide with neuroprotective activity GZK-111. Bulletin of experimental biology and medicine. 2021;172(9):298–302. (In Russ).
29. Kolyasnikova KN, Povarnina PY, Kuznetsova EA., Alyaeva AG, Gudasheva TA, Seredenin SB. Substituted glyproline GZK-111 retains antihypoxic and anxiolytic activity upon oral administration. Khimiko- Farmatsevticheskii Zhurnal. 2021;55(10):10–13. (In Russ).DOI: 10.30906/0023-1134-2021-55-10-10-13.
30. Koliasnikova KN, Povarnina PYu, Tallerova AV, Firsova YuN, Nikolaev SV, Antipova TA, Nadorova AV, Kolik LG, Gudasheva TA, Seredenin SB. Glyproline Pro-Ampakine with Neuroprotective Activity // in: Neuroprotection – New Approaches and Prospects. – IntechOpen. 2020. DOI:10.5772/intechopen.91192.
31. Tallerova AV, Mezhlumyan AG, Yarkova MA, Gudasheva TA, Seredenin SB. Effects of original compounds GSB-106, GML-3, and GZK- 111 in an experimental lipopolysaccharide-induced anhedonia model. Pharmaceutical Chemistry Journal. 2021;55(2):101–105. DOI: 10.1007/s11094-021-02397-x.
32. Konstantinopolsky MA, Gudasheva TA, Kolik LG. Experimental study of endogenous dipeptide Cyclo-L-prolylglycine in aspects of opioid addiction and analgesia in rodents. European Neuropsychopharmacology. 2019;29(3):S180-S181. DOI: 10.1016/j.euroneuro.2018.11.305.
33. Kachalov KS. Issledovaniye ostroy toksichnosti novogo soyedineniya GZK-111. / II nauchnaya konferentsiya molodykh uchenykh s mezhdunarodnym uchastiyem ≪AKTUAL'NYYe ISSLEDOVANIYA V FARMAKOLOGII≫. Materialy konferentsii. FGBNU ≪NII farmakologii imeni V.V. Zakusova≫, 28–29 oct 2021 (In Russ).
34. Kolyvanov GB, Bochkov PO, Litvin AA et al. Metabolism of a new dipeptide neuroprotector in rats. Bulletin of experimental biology and medicine. 2021;172(11):618–621. (In Russ). DOI: 10.47056/0365-9615-2021-172-11-618-621.
Review
For citations:
Koliasnikova K.N., Alyaeva A.G., Kuznetsova E.A. Novel glyproline GZK-111 with neuropsychotropic activity. Pharmacokinetics and Pharmacodynamics. 2021;(4):18-23. (In Russ.) https://doi.org/10.37489/2587-7836-2021-4-18-23
Views:
411
Email this article 